Information Provided By: 
Fly News Breaks for November 29, 2016
NVLS
Nov 29, 2016 | 07:40 EDT
As reported previously, Cowen analyst Phil Nadeau downgraded Nivalis Therapeutics to Market Perform from Outperform. The analyst said its proof-of-concept Phase 2 trial for cystic fibrosis demonstrated no benefits for lung function or sweat chloride, two established measures of activity. The drug was the company's primary asset, Nadeau noted.
News For NVLS From the Last 2 Days
There are no results for your query NVLS
